18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
To elucidate the relationship between cerebrospinal fluid (CSF) total‐tau (T‐tau) and phosphorylated tau (P‐tau) with the tau PET ligand 18 F‐AV‐1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T‐tau and P‐tau were highly correlated ( R = 0.92, P < 0.001), but they were only moderately associated with retention of 18 F‐AV‐1451, and mainly in demented AD patients. 18 F‐AV‐1451, but not CSF T‐tau or P‐tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18 F‐AV‐1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18 F‐AV‐1451 retention was always increased at this disease stage. We conclude that CSF T‐tau and P‐tau mainly behave as biomarkers of “disease state”, since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18 F‐AV‐1451 is a biomarker of “disease stage”, since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This may be in part because P-tau seems to plateau later in the disease [14] while the tau PET signal continues to increase [124].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [124]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AV1451 has a high affinity for pTau-181 related to Alzheimer’s disease by PET imaging [6]; however, AV1451 also displays significant off-target binding [1].”
From Tuberous sclerosis complex is a novel, amyloid-independent tauopathy associated with elevated phosphorylated 3R/4R tau aggregation (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“CSF tau levels demonstrate elevation prior to tau PET imaging, suggesting that it may be a sensitive marker of early change (59).”
From Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Because CSF P-tau and T-tau are highly correlated in AD and are equally correlated with tau PET [124], they do not seem to provide independent information in AD.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [124]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“…a previously described protocol to aggregate FreeSurfer ROIs by their involvement in different stages of tau spread, as determined using 18F-AV-1451 PET in cases with different stages of AD (Cho et al, 2016), and these stages roughly corresponds to the Braak staging approach (Braak & Braak, 1991).”
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324
AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages
Cox, R. W. (1996) · Computers and Biomedical Research · doi:10.1006/cbmr.1996.0014 · Cited by 10,913
Cortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Measuring the thickness of the human cerebral cortex from magnetic resonance images
Fischl, B., & Dale, A. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200033797 · Cited by 5,818
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731 · cited 1×
“Briefly, the T1weighted images underwent correction for intensity homogeneity (Sled et al, 1998), removal of non-brain tissue (Ségonne et al, 2004), and segmentation into grey matter (GM) and white matter (WM) with intensity gradient and connectivity among voxels (Dale et al, 1999; Fischl & Dale,…”
Automatically Parcellating the Human Cerebral Cortex
Fischl, B. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg087 · Cited by 4,253
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
A hybrid approach to the skull stripping problem in MRI
Ségonne, F., Dale, A. M., Busa, E., Glessner, M., Salat, D., Hahn, H. K., & Fischl, B. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.03.032 · Cited by 2,212
Sequence-independent segmentation of magnetic resonance images
Fischl, B., Salat, D. H., van der Kouwe, A. J. W., Makris, N., Ségonne, F., Quinn, B. T., & Dale, A. M. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.016 · Cited by 2,109
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 2×
“Cerebrospinal fluid (CSF) measures of total-tau (T-tau) and phosphorylated tau (P-tau) may reflect axonal degeneration and tangle pathology in AD (Blennow et al, 2010).”
Self-citationDiagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
Spitzer, R. L., & Williams, J. (1987) · Cited by 1,823
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“Note that we adhere to the definitions of disease state and stage biomarkers as presented in (Blennow & Hampel, 2003).”
Self-citationPET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214 · cited 3×
“However, there may also be cohort-dependent differences, since a previous smaller study also reported increased 18F-AV-1451 uptake in Ab-positive controls (Schöll et al, 2016).”
InfluentialSelf-citationTau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Self-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Correction for partial volume effects in PET: principle and validation.
ROUSSET, O. G., Ma, Y., & Evans, A. C. (1998) · PubMed · Cited by 919
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2362 · Cited by 734 · cited 2×
“…et al, 2013; Xia et al, 2013) detects AD-type tau aggregates (Marquié et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and correlates with regional changes in brain…”
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
The Insight ToolKit image registration framework
Avants, B. B., Tustison, N. J., Stauffer, M., Song, G., Wu, B., & Gee, J. C. (2014) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2014.00044 · Cited by 658 · cited 1×
“The anatomical scan was normalized to MNI152 space (Grabner et al, 2006) with a diffeomorphic transform and the Advanced Normalization Tools (ANTs) toolbox (Avants et al, 2014) for further use in the PET processing pipeline (see below; ANTs was used for all coregistrations).”
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“18F-AV-1451 (formerly called 18F-T807; Chien et al, 2013; Xia et al, 2013) detects AD-type tau aggregates (Marquié et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and…”
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“18F-AV-1451 (formerly called 18F-T807; Chien et al, 2013; Xia et al, 2013) detects AD-type tau aggregates (Marquié et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and…”
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Symmetric Atlasing and Model Based Segmentation: An Application to the Hippocampus in Older Adults
Grabner, G., Janke, A. L., Budge, M. M., Smith, D., Pruessner, J., & Collins, D. L. (2006) · Lecture Notes in Computer Science · doi:10.1007/11866763_8 · Cited by 549
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease
Janelidze, S., Zetterberg, H., Mattsson, N., Palmqvist, S., Vanderstichele, H., Lindberg, O., van Westen, D., Stomrud, E., Minthon, L., Blennow, K., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.274 · Cited by 456
Self-citationSchwarz, A. J., Yu, P., Miller, B. B., Shcherbinin, S., Dickson, J., Navitsky, M., Joshi, A. D., Devous, M. D., & Mintun, M. S. (2016) · Brain · doi:10.1093/brain/aww023 · Cited by 425 · cited 1×
“…et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and correlates with regional changes in brain glucose metabolism in AD (Ossenkoppele et al, 2016; Smith et al, 2016b).”
CSF biomarker variability in the Alzheimer's Association quality control program
Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 382
Self-citationPalmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · cited 7×
“This is ~10–15% lower than the concordance for amyloid CSF and PET biomarkers (Palmqvist et al, 2014; Mattsson et al, 2015; Janelidze et al, 2016).”
InfluentialSelf-citationThomas, B. A., Erlandsson, K., Modat, M., Thurfjell, L., Vandenberghe, R., Ourselin, S., & Hutton, B. F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1745-9 · Cited by 316
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Mielke, M. M., Vemuri, P., Lowe, V., Senjem, M. L., Gunter, J. L., Reyes, D., et al. (2015) · Brain · doi:10.1093/brain/awv283 · Cited by 254
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Self-citationCSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Self-citationCSF biomarkers predict a more malignant outcome in Alzheimer disease
Wallin, A. K., Blennow, K., Zetterberg, H., Londos, E., Minthon, L., & Hansson, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dd4dd8 · Cited by 223
Self-citationSensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
Andreasen, N., Minthon, L., Clarberg, A., Davidsson, P., Gottfries, J., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (1999) · Neurology · doi:10.1212/wnl.53.7.1488 · Cited by 212
Self-citationMaia, L. F., Kaeser, S. A., Reichwald, J., Hruscha, M., Martus, P., Staufenbiel, M., & Jucker, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006446 · Cited by 204
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.064 · Cited by 193
Self-citationGordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
18 F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., & Hansson, O. (2016) · Brain · doi:10.1093/brain/aww163 · Cited by 168 · cited 3×
“18F-AV-1451 (formerly called 18F-T807; Chien et al, 2013; Xia et al, 2013) detects AD-type tau aggregates (Marquié et al, 2015; Smith et al, 2016a), differentiates AD patients from controls (Brier et al, 2016; Gordon et al, 2016; Johnson et al, 2016; Schöll et al, 2016; Schwarz et al, 2016) and…”
Self-citationIntra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years
Zetterberg, H., Pedersen, M., Lind, K., Svensson, M., Rolstad, S., Eckerström, C., Syversen, S., Mattsson, U.-B., Ysander, C., Mattsson, N., et al. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12307 · Cited by 128
Self-citationIncreased basal ganglia binding of 18F‐AV‐1451 in patients with progressive supranuclear palsy
Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., et al. (2017) · Movement Disorders · doi:10.1002/mds.26813 · Cited by 118 · cited 2×
“Off-target binding may occur, for example, in the basal ganglia (Smith et al, 2017) and in the choroid plexus, which is close to the hippocampal formation.”
Self-citationTau‐PET uptake: Regional variation in average SUVR and impact of amyloid deposition
Vemuri, P., Lowe, V. J., Knopman, D. S., Senjem, M. L., Kemp, B. J., Schwarz, C. G., Przybelski, S. A., Machulda, M. M., Petersen, R. C., & Jack, C. R. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.010 · Cited by 117
Engelborghs, S., Sleegers, K., Cras, P., Brouwers, N., Serneels, S., De Leenheir, E., Martin, J.-J., Vanmechelen, E., Van Broeckhoven, C., & De Deyn, P. P. (2007) · Brain · doi:10.1093/brain/awm136 · Cited by 113
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
Chhatwal, J. P., Schultz, A. P., Marshall, G. A., Boot, B., Gomez-Isla, T., Dumurgier, J., LaPoint, M., Scherzer, C., Roe, A. D., Hyman, B. T., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003050 · Cited by 106
Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease
Rosén, C., Andréasson, U., Mattsson, N., Marcusson, J. O., Minthon, L., Andreasen, N., Blennow, K., & Zetterberg, H. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8171-4 · Cited by 85
Self-citationCSF biomarkers in neurodegenerative diseases
Mattsson, N. (2011) · cclm · doi:10.1515/cclm.2011.082 · Cited by 74
Self-citationUnderstanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73 · cited 1×
“Alzheimer’s disease (AD) is characterized by extracellular aggregation of amyloid b (Ab) peptides and intracellular aggregation of phosphorylated tau proteins (Zetterberg & Mattsson, 2014).”
Self-citationModeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology
Hahn, A., Schain, M., Erlandsson, M., Sjölin, P., James, G. M., Strandberg, O. T., Hägerström, D., Lanzenberger, R., Jögi, J., Olsson, T. G., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.174508 · Cited by 57
Self-citationDegerman Gunnarsson, M., Ingelsson, M., Blennow, K., Basun, H., Lannfelt, L., & Kilander, L. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0191-0 · Cited by 55
Self-citationGustavsson, A., Stomrud, E., Abul‐Kasim, K., Minthon, L., Nilsson, P. M., Hansson, O., & Nägga, K. (2015) · Cerebrovascular Diseases Extra · doi:10.1159/000377710 · Cited by 46
Self-citationSmith, R., Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., & Hansson, O. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151004 · Cited by 30
Self-citationWiig, E. H., Annas, P., Basun, H., Andreasen, N. C., Lannfelt, L., Zetterberg, H., Blennow, K., & Minthon, L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01160.x · Cited by 24
Self-citation
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“Because CSF P-tau and T-tau are highly correlated in AD and are equally correlated with tau PET [124], they do not seem to provide independent information in AD.”
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationMattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Self-citationthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Metadata
- Authors
- Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- San Francisco VA Medical Center (US)
- Skåne University Hospital (SE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Mattsson, Niklas
- Hansson, Oskar
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2017-07-25
- Volume
- 9
- Issue
- 9
- Pages
- 1212-1223
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC5582410
- OpenAlex
- W2737811824
- Cited by
- 177
- References
- 61
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 20 · 2021: 40 · 2020: 31 · 2019: 30 · 2018: 18 · 2017: 4
- FWCI
- 18.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet
- H2020 European Research Council
- Hjärnfonden
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 18F-AV-1451, tau PET, cerebrospinal fluid tau, total tau, phosphorylated tau, Alzheimer's disease, biomarkers, preclinical Alzheimer's disease, prodromal Alzheimer's disease, Alzheimer's dementia, brain atrophy, cognitive decline, disease stage
- MeSH terms
- Aged, Alzheimer Disease, Brain, Cognition, Female, Fluorine Radioisotopes, Humans, Male, Phosphorylation, Cohort Studies, Biomarkers, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.